6 reports

  • CHAPTER III LUNG CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Lung Cancer Treatment Drugs Production and Demand

It is one major anti-cancers producer in China.

  • Cancer
  • Healthcare
  • Lung Cancer
  • Pharmaceutical
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • CHAPTER IV SKIN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND
  • Retinoids Major Producer and Their Market Share

This study focuses on China’s Skin Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the...

  • Cancer
  • Chemotherapy
  • Skin Cancer
  • Therapy
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • CHAPTER III LUNG CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Major Producer Facility Locations and Output

It is one major anti-cancers producer in China.

  • Cancer
  • Lung Cancer
  • Pharmaceutical
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • Zhejiang Expressway Co., Ltd.
  • Hormones Major Producer and Their Market Share in 2017 (million yuan/percent)
  • CHAPTER IV BRAIN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND

Some brain cancers occur when one type of cell transforms from its normal characteristics.

  • Anti-Infective
  • Brain Cancer
  • Cancer
  • Beijing Novartis Pharma Ltd
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.